Zydus Lifesciences posted a strong performance for the quarter ending September 30, 2024 (Q2 FY25), with robust growth across key financial metrics on a year-over-year (YoY) basis.
- Net Profit: The company’s net profit rose by 13.7% YoY to ₹911 crore, up from ₹801 crore in the same period last year.
- Revenue from Operations: Revenue increased by 20% YoY to ₹5,237 crore, compared to ₹4,368.8 crore in Q2 FY24.
- EBITDA: EBITDA saw a significant jump of 27.5% YoY, reaching ₹1,461.4 crore, up from ₹1,146 crore in the previous year.
- EBITDA Margin: Margins improved, with EBITDA margin standing at 27.9%, up from 26.2% YoY, reflecting enhanced operational efficiency.
These results highlight Zydus Lifesciences’ continued momentum in revenue growth and profitability, supported by effective cost management and an improved operational structure. The company remains well-positioned to sustain its growth trajectory in the coming quarters.
You might also like
4o
